Therapeutic area intelligence for Antimetabolite with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 1

Companies

Nova Labs →

Assets

PURIXAN →

Recent signals(1)

RegulatoryJuly 23, 2026

FDA Approves Supplemental Application for PURIXAN by Nova Labs

The FDA has approved a supplemental application for PURIXAN, an antimetabolite containing mercaptopurine, submitted by Nova Labs.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.